NCT04333160 - Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis | Biotech Hunter

Enrollment

746

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

December 9, 2021

Conditions

Symptomatic Osteoarthritis of the Knee

Interventions

DRUG

JTA-004

Patients will undergo a single intra-articular injection of JTA-004 into the knee joint

DEVICE

Hylan G-F 20

Patients will undergo a single intra-articular injection of Hylan G-F 20 into the knee joint

OTHER

placebo

Patients will undergo a single intra-articular injection of placebo into the knee joint

Trial Locations (22)

1200

Cliniques universitaires Saint-Luc (UCL), Brussels

2000

The Parker Institute, Frederiksberg

2025

"Timofei Mosneaga Republican Clinical Hospital, Sectia Reumatologie,", Chisinau

RTL SM SRL / Institutul de Cardiologie, sectia consultativa, Chisinau

2730

Sanos Clinic, Herlev

3000

UZ Leuven University Hospitals Leuven, Leuven

4020

CHU Liège, Liège

7000

CHU Ambroise Paré, Mons

7100

Sanos Clinic, Vejle

13000

CCR Prague s.r.o, Prague

53002

CCR Czech, a.s, Pardubice

60200

CCR Brno, s.r.o, Brno

Unknown

Sanos Clinic, Gandrup

Hong Kong Center for Clinical Research, Hong Kong

PL35, Bytom

PL37, Gdansk

PL36, Katowice

PL31, Nadarzyn

PL32, Poznan

PL33, Poznan

PL34, Swidnica

St Pancras Clinical Research, London